Drug
Rpesc Rpe 4W
Rpesc Rpe 4W: highest development phase Phase 1/2, developed by Luxa Biotechnology, LLC. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Luxa Biotechnology, LLC
Trials
| Drug | Phase | Indication |
|---|---|---|
| RPESC-RPE-4W NCT04627428 | Phase 1/2 | Dry Age-related Macular Degeneration |
Latest
No recent events.
Follow Rpesc Rpe 4W on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.